This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers.
This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.
Written by:
Alumkal JJ, Herman JG. Are you the author?
Oregon Health & Science University, Knight Cancer Institute, Portland, OR 97239, USA.
Reference: Cancer Discov. 2012 Nov;2(11):979-81.
doi: 10.1158/2159-8290.CD-12-0392
PubMed Abstract
PMID: 23148372
UroToday.com Investigative Urology Section
